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Background: Because of its many desirable properties, etomidate is widely used as an induction 
agent for endotracheal intubation. However, some have recently called into question the safety of 
etomidate for even single-bolus use due to its known effects on adrenal suppression.
Objectives: We sought to compare the in-hospital mortality between septic patients given etomidate 
and those given alternative induction agents for intubation.
Methods: We performed a retrospective chart review of intubated septic patients treated in our 
hospital. We collected data from patients over the age of 18 with sepsis who were intubated in the 
pre-hospital setting, in our emergency department, or on the wards of our hospital, and calculated the 
in-hospital mortality of each group.
Results: We identified 181 patients with sepsis who were intubated over the study period; 135 
received etomidate and 46 received alternative agents or no induction agent. Baseline characteristics, 
vital signs, and laboratory values were similar between the two groups. Of the 46 patients receiving 
alternative agents or no agent, 18 died, yielding an unadjusted mortality of 39.1% (95% CI 25.5% to 
54.6%), while of the 135 patients receiving etomidate, 63 died, for an unadjusted mortality of 46.7% 
(95% CI 38.1% to 55.4%), P=0.38.
Conclusion: We found a non-statistically significant 7.6% absolute increase in mortality in patients 
given etomidate in our small-sized study population.
[WestJEM. 2008;9:195-200.]
etomidate for even single-bolus use, citing its demonstrated 
capacity to cause relative adrenocortical insufficiency after a 
single bolus.6-14 Additionally, a recent retrospective analysis 
suggests an association of etomidate with worse outcomes 
in septic patients.15 Nevertheless, no rigorous, prospective, 
randomized study has demonstrated a clinically significant 
adverse outcome from either continuous or single-dose use of 
etomidate.
In the emergency department (ED), etomidate is widely 
used as an induction agent for endotracheal intubation 
INTRODUCTION
Use of the drug etomidate for continuous sedation 
in mechanically ventilated patients was found to have 
detrimental effects on patient mortality shortly after its 
introduction, presumably because of its measurable adrenal 
suppression. The package insert now cautions against 
prolonged infusion, citing the “hazards of prolonged 
suppression of endogenous cortisol and aldosterone 
production” (Bedford Laboratories, Bedford, OH).1-5 Several 
authors have recently called into question the safety of Volume IX, n o . 4  :  November 2008                                            196                                      Western Journal of Emergency Medicine
because it allows for a rapid, smooth, hemodynamically stable 
intubation.16,17 The implication that etomidate may increase 
mortality, even with a single dose, could have widespread 
effects given the large number of patients who receive this 
medication.
We sought to determine the mortality difference between 
patients with sepsis given etomidate and patients with 
sepsis given alternative induction agents by retrospectively 
reviewing the outcome of intubated septic patients treated in 
our hospital. 
METHODS
Study Design, Setting, and Selection of Participants
This was a retrospective cohort study utilizing a chart 
review of intubated septic patients. The study was performed 
at a tertiary-care suburban community hospital with an annual 
ED census of almost 85,000 patients. We collected data from 
patients over the age of 18 with sepsis who were intubated 
in the prehospital setting, in our ED, or on the wards of 
our hospital over a four-year period from December 2002 
to September 2006. Intubation may have occurred at any 
point during the patient’s hospital stay or in the field prior to 
arrival in the ED. Therefore, intubation was performed by 
paramedics, emergency physicians, house staff physicians, or 
anesthesiologists. The study was approved by the hospital’s 
Institutional Review Board with a waiver of informed consent.
Methods of Measurement
We created a standardized abstraction form using 
Microsoft Excel for recording the patient’s name, age, gender, 
medical record number, induction agent, location and time 
of intubation, admit, discharge date and time, whether or not 
steroids were given, and whether the patient lived or died. We 
trained the additional abstractors in its use through individual 
education about location of the data in the chart. However, we 
were unable to blind abstractors to the study objective or to 
patient assignment.
We identified patients by searching the ED electronic 
medical record database and then confirming the diagnosis of 
sepsis in the inpatient electronic medical record database. We 
searched the terms “sepsis” and “septic” in the diagnosis field 
of the ED records to identify patients in the ED diagnosed as 
septic, and reviewed these charts to determine which patients 
had been intubated (either in the field or in the ED). We then 
searched the ED records for all patients intubated in the ED, 
in order to find patients who had sepsis by standard criteria 
but were given alternative diagnoses in the ED record (such 
as pneumonia, respiratory failure, hypotension, or urinary 
tract infection). Finally, all charts were checked against 
electronic hospital discharge records to ensure that sepsis 
was a discharge diagnosis. Patients found to have had more 
than one admission for sepsis were considered as independent 
admissions. Abstractors were given printed lists of identified 
patient medical record numbers from which to obtain data 
from our ED and inpatient records. Abstraction forms were 
returned to a study coordinator and entered into a master Excel 
spreadsheet.
We recorded into the abstraction forms times of 
admission, intubation, discharge, status at discharge, all 
intubation medications used, any use of supplemental steroids 
Table 1. Demographics and medical history*
Etomidate
N = 135
No Etomidate
N = 46
ED
N = 120 (%)
Floor
N = 15 (%)
ED
N = 16 (%)
Floor
N = 25 (%)
Field
N = 5 (%)
Median Age, years (IQR) 77 (62-83) 69 (61-82) 80 (76-83) 72 (56-76) 81 (63-93)
Gender, % Male 49 60 50 40 80
Diabetes 43 (36) 9 (60) 5 (31) 11 (44) 1 (20)
Coronary Artery Disease 39 (33) 7 (47) 8 (50) 5 (20) 2 (40)
Hypertension 68 (57) 11 (73) 10 (63) 15 (60) 4 (80)
Congestive Heart Failure 37 (31) 6 (40) 6 (38) 8 (32) 1 (20)
COPD 25 (21) 2 (13) 3 (19) 7 (28) 1 (20)
Nursing Home Residence 64 (53) 10 (67) 6 (38) 15 (60) 2 (40)
Immunosuppression 5 (4) 2 (13) 2 (13) 4 (16) 0 (0)
Hemodialysis 9 (8) 1 (7) 1 (6) 4 (16) 0 (0)
Cirrhosis 4 (3) 0 (0) 0 (0) 3 (12) 0 (0)
ED, Emergency Department; COPD, Chronic obstructive pulmonary disease
Immunosuppression includes patients undergoing chemotherapy, radiation, or chronic steroid use, and those diagnosed with leukemia, lymphoma, or 
AIDS.
* Number and percentages are given unless otherwise indicated.
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either in the ED or after admission, as well as laboratory 
values, vital signs, and co-morbidities. Our primary outcome 
was the mortality difference between patients intubated with 
the use of etomidate versus patients intubated using any other, 
or no, induction agent. We selected 10% of our charts for 
review and testing of interrater reliability on the variables of 
etomidate use, steroid use, discharge condition (dead or alive) 
and time of intubation.
Primary Data Analysis
Baseline demographic and clinical characteristics are 
described using means with 95% confidence intervals and 
medians with interquartile ranges (IQRs). We calculated the 
mortality of each of the two groups with 95% confidence 
intervals using the Wilson method with continuity correction 
(VassarStats, http://faculty.vassar.edu/lowry/VassarStats.
html). We compared the unadjusted mortality between the two 
cohorts with a χ2 test and performed survival analysis with 
Kaplan-Meier curves, using the Mantel-Cox Log Rank test to 
compare the two groups. We considered values of P < 0.05 
to be statistically significant for all analyses. Analyses were 
performed using SPSS version 15.0 (SPSS Inc., Chicago, IL). 
RESULTS
We identified 181 patients with sepsis who were 
intubated over the study period. Baseline characteristics 
were similar between the group receiving etomidate and the 
group receiving alternative or no induction agent, although a 
slightly greater percentage of patients in the non-etomidate 
group were immunosuppressed, on hemodialysis, or had 
cirrhosis (Table 1). A greater proportion of patients who did 
not receive etomidate were intubated after admission to the 
hospital when compared to the proportion of patients who did 
receive etomidate. Vital signs and laboratory values, shown in 
Table 2, were not markedly different between the two groups. 
Treatments rendered to patients, summarized in Table 3, were 
likewise not significantly different between groups, as was the 
percent of patients successfully extubated. 
The majority of our patients, 136 (75%) were intubated 
in the ED, 40 (22%) were intubated after admission to the 
hospital, and five (3%) were intubated in the pre-hospital 
setting. Of the 181 patients, 135 received etomidate and 46 
received alternative agents or no induction agent. Steroids 
were given to 108 patients (80%) in the etomidate group 
and 35 patients (76%) in the non-etomidate group. Of the 
Table 2. Vital signs and laboratory values*
Etomidate No Etomidate
Mean 95% Cl Median IQR Mean 95% Cl Median IQR
Mean Arterial Pressure (mm Hg) 75 70 - 80 74 33 74 66 - 82 75 27
Temperature (°C) 37.2 36.8 - 37.5 37.2 1.8 36.8 36.4 - 37.2 36.8 1.1
Heart Rate (beats/min) 109 105 - 114 110 30 103 92 - 114 100 48
Serum:
White Blood Cells (k/μL) 17.7 15.4 - 20.0 14.3 11.7 15.1 12.8 - 17.4 14.8 9.2
Hematocrit (%) 36 34 - 38 37 12 34 30 - 37 37 14
Sodium (mmol/L) 140 139 - 142 139 8 140 138 - 142 139 11
Potassium (mmol/L) 4.8 4.1 - 5.4 4.3 1.2 4.6 4.3 - 4.9 4.4 1.4
Bicarbonate (mmol/L) 20 19 - 22 20 10 25 19 - 31 22 14
Creatinine (mg/dL) 3.1 2.2 - 3.9 1.9 2.2 2.1 1.6 - 2.6 1.7 1.9
pH 7.3 7.28 - 7.33 7.34 0.22 7.26 7.21 - 7.31 7.29 0.32
Lactate (mmol/L) 3.7 3.2 - 4.2 3.1 3 3.9 2.7 - 5.1 2.3 4
IQR, Interquartile range
* Data obtained from times closest to time of intubation.
Table 3. Treatments administered for cohorts
Etomidate No Etomidate
(%) 95% Cl (%) 95% Cl
Percent Receiving:
Antibiotics 97 93 - 99 96 85 - 99
Packed RBC transfusion 36 28 - 44 28 17 - 43
Vasopressors 59 51 - 67 44 30 - 58
Steroids 80 72 - 86 76 62 - 86
Successfully extubated (%) 67 59 - 75 70 55 - 81
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46 patients receiving alternative agents or no agent, 18 died, 
giving a mortality of 39.1% (95% CI 25.5% to 54.6%), while 
of the 135 patients receiving etomidate, 63 died, giving 
a mortality of 46.7% (95% CI 38.1% to 55.4%), P=0.38. 
Kaplan-Meier survival curves, shown in Figure 1, demonstrate 
a divergence that appears to favor the group not receiving 
etomidate, but the difference was not statistically significant 
(P=0.29). Length of ICU stay for patients receiving etomidate, 
4.4 days (95% CI 3.6 to 5.1 days), was similar to patients not 
receiving etomidate, 5.4 days (95% CI 3.9 to 6.9 days). 
All abstractors had full agreement on the use of 
etomidate, steroids, and discharge condition in our subset 
of charts reviewed for interrater reliability. Agreement for 
exact time of intubation was only 67%; however, the median 
disagreement was less than 18 minutes.
DISCUSSION
The primary motivation for the cessation of use of 
etomidate for continuous sedation in the ICU stems from 
a retrospective study of 428 severely injured trauma 
patients.1 In this analysis, the in-hospital mortality rate was 
found to have increased from 28% in those given opiates 
with or without benzodiazepines for sedation to over 70% 
after the adoption of etomidate for continuous sedation, 
despite similar severities of illness in the two groups of 
patients. After the discontinuation of the use of etomidate 
for continuous sedation, mortality returned to 25%. 
Consequently, etomidate use for continuous sedation ceased 
while use as an agent for intubation or procedural sedation 
has continued to increase. Favorable hemodynamic effects 
combined with a lack of immediately evident adverse effects 
makes etomidate particularly appealing for use in critically 
ill patients in the ED.
Although no studies have conclusively shown clinically 
significant adverse outcomes from single-dose use, a recent 
retrospective review of 477 patients by the Corticus Study 
Group found an increased odds ratio of death of 1.53 for 
patients sedated with etomidate.15 Additionally, a number of 
studies have shown adverse effects on surrogate endpoints, 
primarily in adrenocortical output. Reduced plasma cortisol 
and aldosterone levels following induction doses of etomidate 
have been reported to persist for up to 24 hours and appear 
unresponsive to adrenocorticotropic hormone stimulation.7 
Patients given etomidate have shown lower measured serum 
cortisol compared to those given midazolam after cosyntropin 
stimulation tests less than 12 hours after administration and a 
decreased rise in cortisol from a high-dose corticotropin test 
24 hours after intubation.7,18 A retrospective analysis of 152 
patients with septic shock showed decreased responses to 
cosyntropin stimulation in patients given etomidate.9 These 
effects are due to blockage of 11 beta-hydroxylation within the 
adrenal cortex.4
With the widespread use of etomidate in the United States 
for induction of anesthesia prior to intubation, the potential for 
worsened outcomes in septic patients when using etomidate 
has profound implications. In our retrospective chart review, 
we did not find a statistically significant difference in hospital 
mortality between patients given etomidate and patients given 
alternative agents or no induction agent for intubation. The 
baseline demographics, vital signs, and laboratory values 
in the two groups suggest that the patients were similar in 
severity of illness and that neither group would be expected to 
have significantly different outcomes. Likewise, an equivalent 
percentage of patients in each group had been treated with 
steroids.
Although we did not find a statistically significant 
difference in outcomes between our two groups, the difference 
of 7.6% in absolute mortality between groups does raise 
a question of clinical importance. This difference perhaps 
supports the suggestions of others that a well-powered, 
prospective, randomized trial be performed to firmly establish 
the safety of etomidate use in patients at risk of relative 
adrenal insufficiency, such as those with sepsis. Given the 
difference in mortality seen between our patient groups, 
approximately 600 patients per group would be required to 
obtain adequate power to obtain statistical significance, using 
a two-sided α of 0.05 and ß of 0.20. 
LIMITATIONS
For this study, we relied on a chart review from a 
single tertiary care medical center and obtained data 
retrospectively, a method with well-known limitations. 
Although we performed an extensive search for patients, the 
possibility remains that we may not have found all septic 
patients intubated in this time period. We used an objective 
endpoint, discharge or death, limiting the need for observer 
interpretation, but many of our variables (times of intubation, 
Figure 1.  Kaplan-Meier estimates of survival
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types of medication used, comorbidities, vital signs) were 
recorded manually and are therefore subject to potential 
errors of transcription and omission. Although we reviewed 
all sections of the chart to determine which medications were 
used for intubation, including physician entries, nursing 
entries, and pharmacist entries, it remains possible that 
patients we classified as not having received a medication 
such as etomidate or steroids may in fact have received these 
medications, and vice-versa. We received no external funding 
for this study, and thus were unable to hire abstractors that 
could be blinded to the study purpose or to patient treatment. 
Although our endpoints were objective, subtle biases may 
have affected our results in unquantifiable or unexpected 
ways. Despite the inclusion of patients intubated in the 
pre-hospital setting (who were unlikely to have received 
etomidate) we found that a disproportionate number of 
patients received etomidate, weakening the power of our study 
to detect statistically significant differences in mortality. In 
addition, many of the patients who did not receive etomidate 
were intubated either in the field before ED arrival or on the 
hospital floors after treatment in the ED, further contributing 
to possible confounding.
Although we had excellent agreement between abstractors 
in the use of etomidate, the use of steroids, and the final 
discharge disposition (possibly because these items were 
generally documented in identical locations in each electronic 
medical record), we had less than perfect agreement in exact 
times of intubation, since in many cases documentation of 
procedures such as intubation were provided by more than one 
person, including nurses, attending physicians, and resident 
physicians. We limited our dependence on this measure 
by using the day of intubation as our start point and day 
of discharge or death as our endpoint. We examined many 
commonly used variables to evaluate differences in severity of 
illness between patient groups, but many charts did not have 
a documented Glasgow Coma Scale (GCS) score, limiting 
our ability to calculate scores such as a Simplified Acute 
Physiology Score or an Acute Physiology and Chronic Health 
Evaluation score. We did not attempt to estimate GCS scores 
from the charts we reviewed. The fact remains that the clinical 
appearance of the patient is often not reflected in severity 
of illness scores, and that unmeasured differences may exist 
between our cohorts that might explain the difference in 
mortality that we observed. Moreover, the differences in 
location of intubation between groups may also explain these 
mortality differences. 
CONCLUSION
We found a non-statistically significant 7.6% absolute 
difference in mortality between patients given etomidate and 
patients given alternative or no induction agent for intubation 
in our study population, although the study was limited by 
a small sample size. Given the magnitude of this difference, 
further investigation into the safety of etomidate when used 
in patients at risk of relative adrenal insufficiency may be 
warranted; however, the available evidence to date does not 
support abandoning the use of etomidate in patients with 
sepsis. 
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